CD­MOs Nephron and Can­ton each raise hun­dreds of mil­lions in fi­nanc­ing

Nephron Phar­ma­ceu­ti­cals and Can­ton Bi­o­log­ics re­cent­ly an­nounced cap­i­tal rais­es to­tal­ing hun­dreds of mil­lions of dol­lars, join­ing the grow­ing mar­ket for con­tract and de­vel­op­ment man­u­fac­tur­ing com­pa­nies.

South Car­oli­na-based Nephron said Fri­day that it raised $350 mil­lion for “fu­ture growth.” Nephron de­vel­ops and pro­duces gener­ic in­hala­tion so­lu­tions and sus­pen­sion prod­ucts as well as op­er­ates an out­sourc­ing fa­cil­i­ty that makes prod­ucts like pre-filled sy­ringes and IV bags for hos­pi­tals that aim to help mit­i­gate drug short­ages.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.